A multi-BILLION-Euro Swiss finance house has launched Pictet-Longevity as a vehicle to invest in companies in the ageing space.
Founded by Pictet Asset Management the new entity will aim to capitalise on ‘the economic implications of ageing populations’.
Lead manager Marien-Baptiste Pouyat said: “By uniting our health and human experience under Pictet-Longevity, we can capitalize on the opportunities presented by societal developments.
“’Through this strategy, we’re investing in businesses that are driving innovation and delivering sustainable returns for our investors.
It will invest in two key areas, namely Health Span – companies offering established and efficient healthcare solutions’ – and Productivity – technology-driven innovations that help businesses operate efficiently as societies age.
It estimates the global longevity market at roughly $3.5tn, with expected compound annual growth of 9%.
Living To 150?
Miami-based wealth managers Insigneo have flagged-up the need to rethink global financing as the world awakens to an on-going ‘longevity boom’
Speaking at Insigneo’s 2025 Summit in Seville, CIO Ahmed Riesgo highlighted longevity’s potential as an ‘investable megatrend’
He singled out health, technology and longevity real estate and infrastructure as sectors with structural investment advantages.
Nasdaq-listed Psyence Biomedical has launched a new psilocybin longevity research initiative in collaboration with leading South African researchers.
This program positions Psyence as the first publicly-listed US company to investigate psilocybin’s potential impact on biological markers associated with ageing and longevity.
Chinese firm Lonvi Biosciences claims its new drug could stretch human life to 150 years.
The Shenzhen-based company says its new development targets so-called ’zombi’ or ageing cells that refuse to die, triggering inflammation and age-related disease.
“This is not just another pill. This is the Holy Grail,” said CEO Ip Zhu, describing the capsule as a breakthrough that could make extreme longevity a reality.
The drug’s key ingredient, procyanidin C1, is derived from grape seeds and has shown lifespan extension in lab animals.
London biotech company Istesso says its lead candidate in musculoskeletal repair, leramistat, also has potential treatment capabilities for age-related degenerative conditions.
Its announcement follows detailed analyses from a Phase 2b rheumatoid arthritis trial, which revealed signals far beyond joint inflammation, including bone protection and early signs of muscle preservation.
Leramistat, an oral mitochondrial complex I modulator, is designed to activate the body’s intrinsic repair machinery.
Dr Lisa Patel, Istesso’s CEO, said: “The potential of leramistat to directly target the muscle is hugely exciting. This confirms our view that our novel MCMs offer a new path to stopping, or even reversing, progressive tissue decline.”
Pomegranate Powerhouse
Scientists at the Georg-Speyer-Haus and University Medicine Frankfurt have successfully demonstrated that a natural substance derived from pomegranates can turn back the clock on key aspects of immune ageing.
In a phase I clinical trial published in Nature Aging the team led by Prof Florian Greten and Dr Dominic Denk examined the potential of Urolithin A.
A key driver of ageing decline is the loss of T cells. Its randomised, double-blind, placebo-controlled trial involved 50 healthy, middle-aged adults who received a daily dose of Urolithin A or a placebo for four weeks.
Participants who received Urolithin A showed a significant increase in their T cells, effectively replenishing their pool of ‘young’ immune cells (6).
New research from Sentai, a conversational AI voice companion tool, reveals that loneliness now rivals falls as one of the top fears for families with elderly relatives living alone.
While 47% of families say they worry most about falls, 41% are equally fearful of loneliness, and 65% admit concern about their loved ones feeling isolated.
Paul Statham, CEO of Sentai, said: “We often think of safety in physical terms, avoiding accidents or falls, but our research proves loneliness is just as frightening for families. Sentai is designed as a companion as well as a safety net, because staying connected is what truly keeps people well.”
Sentai’s approach combines companionship, reminders, and reassurance to help families act earlier, reducing both the emotional and physical toll of living alone, and keeping older adults connected, supported, and safe.